Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: GlobeNewswire
Advancement of Fast Skeletal Muscle Troponin Activator Expands Pipeline of Muscle-Directed Drug Candidates SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose clinical study of CK-4015089 (CK-089) in healthy human participants. CK-089 is a fast skeletal muscle troponin activator (FSTA) with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired muscle function. “We are pleased to begin clinical development of CK-089, a promising fast skeletal muscle troponin activator arising from our research in neuromuscular diseases,” said Stuart Kupfer, M.D., Senior Vice President, Chief Medical Officer. “In the pre-clinical setting, CK-089 increased muscle force and function in animal models of a neuromuscular disease charact
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics to Announce Fourth Quarter Results on February 27, 2025GlobeNewswire
- Cytokinetics, Incorporated (NASDAQ: CYTK) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $67.00 price target on the stock, down previously from $70.00.MarketBeat
- Cytokinetics Names Robert E. Landry to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Cytokinetics, Incorporated (NASDAQ: CYTK) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
- Cytokinetics Names Robert E. Landry to Board of DirectorsGlobeNewswire
CYTK
Earnings
- 11/6/24 - Miss
CYTK
Sec Filings
- 2/12/25 - Form SCHEDULE
- 2/11/25 - Form 4
- 2/11/25 - Form 3
- CYTK's page on the SEC website